RYBREVANTTM (amivantamab-vmjw) in the Treatment of Patients with Advanced Non-Small.
The Pharma Data
AUGUST 19, 2021
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary data from the Phase 1 CHRYSALIS study evaluating RYBREVANT TM (amivantamab-vmjw) for the treatment of patients with non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition (MET) exon 14 skipping (METex14) mutations. 4] , [5] , [6].
Let's personalize your content